Daniel Sanghoon Shin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207781/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports, 2017, 19, 1189-1201.	6.4	1,256
2	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. Cancer Discovery, 2017, 7, 188-201.	9.4	997
3	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	9.4	367
4	PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research, 2016, 4, 194-203.	3.4	321
5	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology, 2015, 33, 23-35.	5.5	298
6	Repurposing metformin for cancer treatment: current clinical studies. Oncotarget, 2016, 7, 40767-40780.	1.8	252
7	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine, 2020, 12, .	12.4	77
8	Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood, 2010, 116, 5162-5169.	1.4	48
9	Membrane Topological Analysis of the Proton-Coupled Folate Transporter (PCFT-SLC46A1) by the Substituted Cysteine Accessibility Method. Biochemistry, 2010, 49, 2925-2931.	2.5	46
10	Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Molecular Genetics and Metabolism, 2011, 103, 33-37.	1.1	42
11	Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. American Journal of Physiology - Cell Physiology, 2010, 299, C1153-C1161.	4.6	39
12	A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. American Journal of Physiology - Cell Physiology, 2012, 302, C1405-C1412.	4.6	31
13	Identification of a functionally critical GXXG motif and its relationship to the folate binding site of the proton-coupled folate transporter (PCFT-SLC46A1). American Journal of Physiology - Cell Physiology, 2012, 303, C673-C681.	4.6	31
14	Role of the fourth transmembrane domain in proton-coupled folate transporter function as assessed by the substituted cysteine accessibility method. American Journal of Physiology - Cell Physiology, 2013, 304, C1159-C1167.	4.6	24
15	Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discovery, 2019, 5, 62.	6.7	20
16	Random Mutagenesis of the Proton-coupled Folate Transporter (SLC46A1), Clustering of Mutations, and the Bases for Associated Losses of Function. Journal of Biological Chemistry, 2011, 286, 24150-24158.	3.4	19
17	Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer. Journal of Biological Chemistry, 2020, 295, 17169-17186.	3.4	19
18	Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption. American Journal of Physiology - Cell Physiology, 2012, 303, C834-C842.	4.6	15

#	Article	IF	CITATIONS
19	Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification. Case Reports in Oncology, 2016, 9, 298-304.	0.7	15
20	Vulnerability of the cysteine-less proton-coupled folate transporter (PCFT-SLC46A1) to mutational stress associated with the substituted cysteine accessibility method. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1140-1145.	2.6	14
21	Substitutions that lock and unlock the proton-coupled folate transporter (PCFT-SLC46A1) in an inward-open conformation. Journal of Biological Chemistry, 2019, 294, 7245-7258.	3.4	7
22	Leucocytosis and Stroke in a Lung Cancer Patient. European Journal of Case Reports in Internal Medicine, 2019, 7, 001872.	0.4	4
23	Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report. Journal of Medical Case Reports, 2021, 15, 216.	0.8	3
24	Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Reports, 2014, 2014, bcr2013203400-bcr2013203400.	0.5	3
25	Romiplostim mitigates dose-limiting thrombocytopenia of erucic acid for adrenomyeloneuropathy. British Journal of Haematology, 2015, 171, 879-881.	2.5	2